Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 6/20 | 0.55 |
| ▸ | F2 | P00734 | 4/20 | 0.55 |
| ▸ | F10 | P00742 | 4/20 | 0.55 |
| ▸ | PLG | P00747 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
| ▸ | ACE | P12821 | 7/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058308 | 0.90 | TMPRSS11D (0.52) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL19390241 | 0.87 | ACE (0.53) | TMPRSS11DLTA4HACELMNA | |
| SCHEMBL12969021 | 0.87 | TMPRSS11D (0.60) | TMPRSS11DF2F10PLGLTA4H | |
| SCHEMBL10058208 | 0.87 | TMPRSS11D (0.60) | TMPRSS11DF2F10PLGLTA4H | |
| SCHEMBL12968410 | 0.87 | TMPRSS11D (0.59) | TMPRSS11DF2F10PLGACE | |
| SCHEMBL15139664 | 0.87 | ACE (0.51) | TMPRSS11DF2F10PLGLTA4H | |
| SCHEMBL15251895 | 0.85 | ACE (0.54) | TMPRSS11DLTA4HACELMNA | |
| SCHEMBL15251683 | 0.85 | ACE (0.54) | TMPRSS11DLTA4HACELMNA | |
| SCHEMBL15251684 | 0.85 | ACE (0.54) | TMPRSS11DLTA4HACELMNA | |
| SCHEMBL19390145 | 0.85 | TMPRSS11D (0.57) | TMPRSS11DF2F10PLGLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655399-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012083436-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | F2, F12, SERPINC1 | TMPRSS11D 49/4885F2 1/4885F10 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.